Literature DB >> 24980560

Initial experience with the Gore® Acuseal graft for prosthetic vascular access.

Matteo Tozzi1, Marco Franchin, Giuseppe Ietto, Gabriele Soldini, Giulio Carcano, Patrizio Castelli, Gabriele Piffaretti.   

Abstract

PURPOSE: The purpose of this study is to report the short-term results of the Gore® Acuseal graft for prosthetic vascular access (pVA) in patients with end-stage renal disease on hemodialysis.
METHODS: Between October 2011 and October 2013, all the consecutive patients who underwent implantation of a new expanded Polytetrafluoroethylene (ePTFE) tri-layer graft were included in the study. Primary and secondary patency rate, time to first cannulation, and complications were recorded. Follow-up was performed at 1, 3, 6, and 12 months after the intervention.
RESULTS: Thirty ePTFE tri-layer heparin bonded grafts were implanted in 18 males and 12 females. The graft configuration was radial-basilic (n=12, 40%), brachial-basilic (n=10, 33.3%), femoro-femoral (n=3, 10.0%), radial-cephalic (n=2, 6.7%), radial-antecubital forearm (n=2, 6.7%), and brachial-axillary (n=1, 3.3%). No patient was lost during a mean follow-up time of 6.3±5.9 months (range, 1-24; median, 5). Mean time to first cannulation was 2.4±1.2 days (range, 1-15). Primary functional patency rate was 68.0% ± 10 at 6 and 12 months. Secondary patency rate was 93.3% ± 6 at 6 and 12 months. Pseudoaneurysm, bleeding, seroma, or graft infection was never observed.
CONCLUSIONS: In our experience, the Gore® Acuseal graft was useful and safe. Early cannulation was always performed, and structural complications did not occur. Primary functional and secondary patency rate are satisfactory in the short term.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24980560     DOI: 10.5301/jva.5000276

Source DB:  PubMed          Journal:  J Vasc Access        ISSN: 1129-7298            Impact factor:   2.283


  5 in total

1.  Immediate-access grafts provide comparable patency to standard grafts, with fewer reinterventions and catheter-related complications.

Authors:  Jason K Wagner; Ellen Dillavou; Uttara Nag; Adham Abou Ali; Sandra Truong; Rabih Chaer; Eric Hager; Theodore Yuo; Michel Makaroun; Efthymios D Avgerinos
Journal:  J Vasc Surg       Date:  2018-10-24       Impact factor: 4.268

Review 2.  Patency of ePTFE Arteriovenous Graft Placements in Hemodialysis Patients: Systematic Literature Review and Meta-Analysis.

Authors:  Ronald J Halbert; Gina Nicholson; Robert J Nordyke; Alison Pilgrim; Laura Niklason
Journal:  Kidney360       Date:  2020-10-15

Review 3.  Outcome of GORE® ACUSEAL graft for brachial-axillary vascular access in chronic haemodialysis patients: Cohort retrospective single-centre study.

Authors:  Tamer Sayed; Mahmoud Montasser; Yasser Ashoor; Ahmed Saad
Journal:  Ann Med Surg (Lond)       Date:  2020-11-17

4.  Patient characteristics predict patency of early-cannulation arteriovenous grafts.

Authors:  David B Kingsmore; Karen S Stevenson; S Richarz; Andrej Isaak; Andrew Jackson; Ram Kasthuri; Peter C Thomson
Journal:  Sci Rep       Date:  2021-05-24       Impact factor: 4.379

5.  Myointimal Hyperplasia in a Patient with Neuromyelitis Optica (Devic's Disease) after the Creation of an Arteriovenous Graft.

Authors:  Christina Rao; Stephanie Fox; Sapan S Desai
Journal:  Case Rep Neurol       Date:  2017-11-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.